Precigen Inc PGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
Trading Information
- Previous Close Price
- $4.66
- Day Range
- $4.51–4.71
- 52-Week Range
- $3.04–8.98
- Bid/Ask
- $4.48 / $4.53
- Shares Outstanding
- 358.55M
- Market Cap
- $1.63B
- Volume/Avg
- 4M / 6M
Key Statistics
- Price/Earnings (Normalized)
- 32.08
- Price/Sales
- 11.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 47
- Website
- http://www.precigen.com
Valuation
Metric | PGEN |
|---|---|
Price/Earnings (Normalized) | 32.08 |
Price/Book Value | 19.36 |
Price/Sales | 11.54 |
Price/Cash Flow | 46.91 |
Price/Earnings
No chart available
Financial Strength
Metric | PGEN |
|---|---|
Quick Ratio | 4.63 |
Current Ratio | 5.58 |
Interest Coverage | 2.88 |
Quick Ratio
PGEN
Profitability
Metric | PGEN |
|---|---|
Return on Assets (Normalized) | 21.72% |
Return on Equity (Normalized) | 87.53% |
Return on Invested Capital (Normalized) | 32.86% |
Return on Assets
PGEN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|mmT%MC | LOCK|Vqb&% | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@DS<$Nc | LOCK|<Ss@ | $99B | |||
| Moderna Inc MRNA | LOCK|?@>J>$ | LOCK|Nx | $90B | |||
| argenx SE ADR ARGX | LOCK|lN%<xX | LOCK|wQ% | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|SKc<JL> | LOCK|z# | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|D!cS#<< | LOCK|c^<J | $31B | |||
| Incyte Corp INCY | LOCK|SQmm!p | LOCK|G! | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|fKX?cH | LOCK|qDr% | $22B | |||
| BioNTech SE ADR BNTX | LOCK|W!&!>?^ | LOCK|^%c | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|sVG@WH& | LOCK|<Q# | $16B |
United States